SCHEMBL30633127

SCHEMBL30633127

CCOC(=O)Nc1cc(-c2ccc3[nH]nc(N)c3c2)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 11/20 0.48
▸ PIK3C3 Q8NEB9 3/20 0.48
▸ JAK3 P52333 4/20 0.47
▸ DYRK1A Q13627 4/20 0.47
▸ PLK4 O00444 3/20 0.47
▸ DAPK3 O43293 3/20 0.47
▸ DYRK3 O43781 3/20 0.47
▸ ROCK2 O75116 3/20 0.47
▸ MAP4K4 O95819 3/20 0.47
▸ CDK1 P06493 3/20 0.47
▸ CDK2 P24941 3/20 0.47
▸ MARK3 P27448 3/20 0.47
▸ TYK2 P29597 3/20 0.47
▸ CLK2 P49760 3/20 0.47
▸ CDK5 Q00535 3/20 0.47
▸ PRKCD Q05655 3/20 0.47
▸ ROCK1 Q13464 3/20 0.47
▸ PKN2 Q16513 3/20 0.47
▸ MARK2 Q7KZI7 3/20 0.47
▸ AURKB Q96GD4 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26886635 1.00 JAK2 (0.48) JAK2PIK3C3JAK3DYRK1APLK4
SCHEMBL30633309 0.86 PIK3C3 (0.40) JAK2PIK3C3JAK3DYRK1APLK4
SCHEMBL26686340 0.85 JAK2 (0.56) JAK2JAK3DYRK1APLK4DAPK3
SCHEMBL31420523 0.84 PIK3C3 (0.47) PIK3C3JAK3ROCK2ROCK1MAPK1
SCHEMBL31240315 0.83 MAPK1 (0.56) JAK2JAK3DYRK1APLK4DAPK3
SCHEMBL26685764 0.83 MAPK1 (0.56) JAK2JAK3DYRK1APLK4DAPK3
SCHEMBL31420740 0.83 PIK3C3 (0.45) PIK3C3JAK3MAPK1GSK3B
SCHEMBL30633351 0.83 PIK3C3 (0.45) PIK3C3JAK3MAPK1GSK3B
SCHEMBL26888293 0.83 PIK3C3 (0.45) PIK3C3JAK3MAPK1GSK3B
SCHEMBL31240475 0.82 MAPK1 (0.57) JAK2JAK3DYRK1APLK4DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US claimed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP claimed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO claimed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO claimed
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB JAK2 207/4885PIK3C3 575/4885JAK3 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback